Demand and volumepositive · 4 filings
“This decrease was partially offset by increased production volumes due to increases in demand for tissue products from 4C in 2026.”10-Q · May 12, 2026 ↗
Anteris Technologies Global Corp.
AVR
You’ve read what changed. Here’s whether the market is confirming it.
Market read
Anteris Technologies Global Corp.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 25 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.
Distributor1
Supplier1
Partner2
Company-3.0% todayVolume comparison unavailable
Market group0 of 25 activeFinancial Services & Tech · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- AVR's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AVR's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 25 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- AVR's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods2
Price observations319
Usable filing statements37
Verified relationships10
Evidence supporting the case
- Demand and volume has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Latest annual revenue changed -29.2% year over year.
- Operating margin changed -2008.8 percentage points in the latest annual period.
- Net margin changed -2098.8 percentage points in the latest annual period.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
8.306m+27.5%12m+126.8%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2024-12-31$2.7M—$-3.68—
2025-12-31$1.9M-29.2%$-2.55—
What management says matters
Persistent and emerging business drivers
Foreign exchangenegative · 4 filings
“Net Foreign Exchange (Losses)/Gains Net foreign exchange losses during the three months ended March 31, 2026 were $0.1 million compared to $0.2 million of net foreign exchange losses for the same period in the prior year, which amounted to a decrease of $0.1…”10-Q · May 12, 2026 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
8.28-3.0% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:00 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for AVR. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for AVR. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind AVR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LMATLeMaitre Vascular, Inc.distributorMay 12, 2026 ▾
“Such sales have historically been made principally to 4C Medical Technologies, Inc.”
LMATLeMaitre Vascular, Inc.supplierNov 12, 2025 ▾
“Concurrent with such sale, we entered into a Transition Services Agreement pursuant to which we manufactured and sold CardioCel™ and VascuCel™ products to LeMaitre.”
Depended on by
AORTArtivion, Inc.competitorMay 8, 2026 ▾
“We compete with these xenograft products from companies including Edwards Lifesciences, Anteris Technologies, Abbott Laboratories, and Baxter.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AVR is currently a Follower in the organic co-movement group Financial Services & Tech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AVR; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.